Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.56 |
| ▸ | MDM4 | O15151 | 10/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057199 | 0.98 | MDM2 (0.59) | MDM2MDM4PLAUPCSK9RXFP4 | |
| SCHEMBL16167588 | 0.94 | MDM2 (0.64) | MDM2MDM4PCSK9RXFP4 | |
| SCHEMBL16167598 | 0.92 | MDM2 (0.68) | MDM2MDM4PCSK9RXFP4 | |
| SCHEMBL16351425 | 0.89 | MDM4 (0.49) | MDM2MDM4PLAUPCSK9SSTR1 | |
| SCHEMBL16351424 | 0.87 | MDM2 (0.53) | MDM2MDM4PLAUPCSK9SSTR1 | |
| SCHEMBL19406735 | 0.80 | MDM2 (0.62) | MDM2MDM4PCSK9 | |
| SCHEMBL15183815 | 0.78 | MDM4 (0.47) | MDM2MDM4PLAUPCSK9TSLP | |
| SCHEMBL19406734 | 0.76 | MDM2 (0.67) | MDM2MDM4PCSK9 | |
| SCHEMBL15183812 | 0.76 | MDM2 (0.51) | MDM2MDM4PLAUTSLPKDM4A | |
| SCHEMBL15183813 | 0.76 | MDM2 (0.66) | MDM2MDM4PCSK9F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257716-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257716-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | MDM2 2533/4885MDM4 3015/4885PLAU 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.